Telehealth ADHD Prescribing: What Psychiatrists Can Do in California

You’re a psychiatrist who’s spent years building your practice. You know ADHD inside and out—the diagnostic nuances, the medication titration dance, the fine line between therapeutic benefit and side effect burden. But lately, you’ve been wondering: Can I actually prescribe Adderall through a video visit? What about that Ryan Haight Act I keep hearing about? And if my state allows it, is it even worth the regulatory headache?

Let’s cut through the noise. As of February 2026, yes—psychiatrists can prescribe ADHD medications including Schedule II stimulants via telehealth, but with important caveats that vary by timing and location. The pandemic-era federal flexibility that made this possible has been extended through December 31, 2025, and while we’re now in early 2026, the regulatory landscape remains in flux. More importantly, whether you should lean into telehealth ADHD care depends on understanding the real economics, the state-specific rules, and how platforms like Klarity Health remove the barriers that trip up most solo practitioners.

Here’s what you actually need to know to make this work for your practice—and your patients.

The Federal Framework: Where Telehealth ADHD Prescribing Stands in 2026

The Ryan Haight Act and COVID-Era Waivers

Under normal circumstances, the Ryan Haight Act (passed in 2008) requires at least one in-person medical evaluation before a practitioner can prescribe controlled substances via telemedicine. For ADHD treatment—where first-line medications like Adderall, Vyvanse, and Ritalin are Schedule II controlled substances—this would essentially kill telehealth prescribing before it starts.

But we’re not operating under normal circumstances. When COVID hit in 2020, the DEA issued temporary waivers allowing providers to initiate controlled substance prescriptions entirely through telehealth encounters, no in-person visit required. These flexibilities have been extended multiple times, most recently through the end of 2025 (www.axios.com).

As of February 2026, we’re in a gray area. The third extension pushed the deadline into 2025, but federal agencies haven’t issued a permanent rule or further extension yet (www.axios.com). This means:

• Right now: You can still prescribe stimulants to new telehealth patients without an initial in-person exam under the extended waiver
• The uncertainty: If no permanent solution emerges, we could revert to requiring in-person visits for new controlled substance patients
• The practical reality: Most providers are continuing telehealth ADHD care while preparing contingency plans

Congress has shown support for extending these flexibilities—mental health access is a political priority and the telehealth genie isn’t going back in the bottle. But until permanent legislation passes or the DEA issues a final rule (they’ve floated the idea of a ‘special telemedicine registration’), you need to stay current on federal policy and have backup plans.

What This Means for Your Practice

If you’re a psychiatrist considering telehealth ADHD care, the federal framework is actually quite workable right now:

You can:

• Conduct initial ADHD evaluations via synchronous video
• Prescribe Schedule II stimulants (Adderall, Vyvanse, Ritalin, etc.) to new patients through e-prescribing
• Continue managing existing ADHD patients entirely through telehealth
• Practice across state lines (if you hold licenses in those states)

You must:

• Use a DEA-compliant e-prescribing platform with two-factor authentication
• Maintain the same standard of care as in-person visits (thorough evaluation, documented diagnosis, monitoring plan)
• Have a valid DEA registration and state license where the patient is located
• Check your state’s Prescription Drug Monitoring Program (PDMP) before prescribing

The key difference between you and other providers: As a psychiatrist (MD/DO), you face no additional state-level restrictions on your prescribing authority. This is huge, and we’ll get to why in a moment.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where You Can Actually Do This

Federal law sets the floor, but states add their own wrinkles. Here’s what matters for telehealth ADHD prescribing in key markets:

States That Explicitly Welcome Telehealth ADHD Care

Florida might be the clearest example. Florida law explicitly allows healthcare providers to prescribe Schedule II controlled substances via telehealth for psychiatric disorders (www.flsenate.gov) (www.flsenate.gov). Florida carved out mental health treatment from its general restrictions on controlled substance teleprescribing—so you can start an adult on Adderall through a video visit in Tampa just as legitimately as seeing them in your office.

Texas allows teleprescribing of controlled substances for mental health conditions through live video (audio-video, not just phone) (www.cchpca.org). Texas explicitly prohibits telehealth controlled substance prescribing for chronic pain management (www.cchpca.org), but ADHD treatment doesn’t fall under that restriction. You need synchronous video (not audio-only) to prescribe controlled substances, but otherwise Texas gives psychiatrists a clear path.

California, New York, Pennsylvania, and Illinois generally follow federal guidelines without imposing additional state-level barriers for psychiatrists prescribing ADHD medications via telehealth. Each has nuances around e-prescribing mandates and PDMP checks, but none prohibit what you’re trying to do.

The Critical Difference: You’re a Psychiatrist

Here’s where your MD/DO makes all the difference. While psychiatric nurse practitioners (PMHNPs) face a patchwork of state restrictions—required collaborations, quantity limits, even outright bans on Schedule II prescribing in some states—psychiatrists have full, independent prescribing authority in every state.

Consider Texas: a PMHNP in Texas cannot prescribe Schedule II stimulants to outpatient ADHD patients at all under state law (they’re limited to hospital or hospice settings) (rxagent.co). You, as a psychiatrist? No such restriction. You can build an entire telehealth ADHD practice in Texas serving patients statewide.

Florida limits PMHNPs to 7-day supplies of Schedule II medications unless they’re working under a psychiatrist’s protocol as a ‘psychiatric nurse’ (rxagent.co). Again, doesn’t apply to you.

Pennsylvania limits NPs to 72-hour initial prescriptions of Schedule IIs with physician notification (rxagent.co). You can write a 30-day prescription from day one.

This scope freedom isn’t just regulatory convenience—it’s a massive competitive advantage. Telehealth platforms need psychiatrists precisely because of these restrictions. Many states have severe psychiatry shortages (Texas has roughly 1 psychiatrist per 9,000 residents (www.healingpsychiatryflorida.com), Florida about 1 per 8,500 (www.healingpsychiatryflorida.com)), yet their laws make it difficult for NPs to fill the gap independently. You can step into that void.

The Clinical Reality: What ADHD Telehealth Actually Looks Like

Let’s talk about what you’ll actually be doing day-to-day. ADHD medication management via telehealth isn’t fundamentally different from in-office care—it’s the logistics and documentation that matter.

Initial Evaluation

A comprehensive ADHD evaluation typically takes 45-60 minutes. Via video, you’re covering:

• Detailed symptom history using DSM-5 criteria (inattention, hyperactivity, impulsivity)
• Developmental history (When did symptoms start? School performance? Previous diagnoses?)
• Functional impairment (Work? Relationships? Daily tasks?)
• Comorbidity screening (Anxiety, depression, substance use, sleep disorders)
• Collateral information when possible (prior testing, school records for children, partner observations for adults)
• Rating scales sent electronically (ADHD-RS, ASRS for adults, Vanderbilt for children)

You can observe attention, focus, and impulse control through the screen. Most adult ADHD patients are perfectly capable of engaging in a structured video interview—if anything, the lower-stimulation environment (no waiting room, familiar home setting) sometimes yields more accurate assessment than an office might.

For vitals monitoring, you’ll either ask patients to obtain blood pressure/heart rate at a pharmacy or primary care visit before starting stimulants, or have them purchase a home BP cuff. It’s an extra step but entirely workable, and frankly, getting patients engaged in their own monitoring often improves adherence.

Medication Initiation

Once you’ve confirmed ADHD diagnosis, you’re e-prescribing through a HIPAA-compliant, DEA-registered platform. You’ll check the state PDMP first—most states require this for Schedule II prescriptions or strongly encourage it. For a first-time patient with no red flags, this takes 2-3 minutes.

You start conservatively: maybe Adderall XR 10mg or Vyvanse 30mg, explaining the expected effects, side effect profile, and when to follow up. You write the prescription for 30 days (the standard for Schedule II—federal law prohibits refills, so every month requires a new prescription).

Documentation matters more in telehealth. You need to clearly record:

• Patient location (which state they’re in during the visit—this determines jurisdiction)
• Mode of communication (video, specifics of the platform)
• Informed consent for telehealth and stimulant therapy
• Diagnostic rationale meeting DSM-5 criteria
• Consideration of alternative diagnoses and comorbidities
• Treatment plan and monitoring schedule

This documentation isn’t busywork—it’s your protection if anyone questions the appropriateness of prescribing controlled substances remotely.

Follow-Up Management

ADHD medication management is actually ideal for telehealth. Follow-ups are typically 15-20 minutes, monthly initially, then potentially every 2-3 months once stable. You’re assessing:

• Efficacy: Are symptoms improving? Functional gains at work/school?
• Side effects: Appetite suppression, sleep issues, anxiety, elevated BP/HR?
• Adherence: Taking as prescribed? Any concerning patterns?
• Diversion risk: Any requests for early refills, lost prescriptions, concerning behaviors?

These conversations happen just as effectively over video as in person—perhaps more so, since patients often report being more candid in their home environment without the clinical power dynamic of an office.

You’ll periodically have patients recheck vitals (every 3-6 months for stable patients is typical). Some platforms coordinate this with primary care, others have patients report home measurements. The key is having a system.

Managing the Medication Shortage Crisis

Here’s a reality of ADHD practice in 2026 that nobody warned you about in residency: stimulant shortages are still a problem. Adderall and other ADHD medications have been in shortage since late 2022 (www.axios.com), with prescriptions surging during the pandemic (apnews.com) and manufacturing not keeping pace.

This means you’ll spend time:

• Calling pharmacies to find who has medication in stock
• Switching patients between generics or to alternative stimulants (methylphenidate if they’re on amphetamine, or vice versa)
• Sometimes trying non-stimulants (atomoxetine, guanfacine) as bridges

It’s frustrating but manageable. Having a telehealth platform that helps coordinate pharmacy logistics is valuable—you shouldn’t be the one making 10 pharmacy calls per patient.

The Economics: Does Telehealth ADHD Care Actually Pay?

Let’s be blunt: you’re not doing this for altruism alone. Can you make a living doing telehealth ADHD medication management? Absolutely—but the math works very differently than most psychiatrists assume.

Insurance Reimbursement Reality

The good news: telehealth payment parity is nearly universal for mental health services in 2026 (behavehealth.com). Medicare, Medicaid (in most states), and commercial insurers pay the same rate for video visits as in-person for psychiatric services.

For medication management, you’re typically billing:

• 99214 (25-minute established visit): Medicare pays ~$125, commercial often $140-180 (therathink.com)
• 99213 (15-minute visit): Medicare ~$90, commercial $100-130
• 90792 (initial psychiatric evaluation with medical services): Medicare ~$190-200 (therathink.com)

If you’re in-network, you can build a sustainable practice. Four 15-minute med checks per hour at $100 average = $400/hour gross. Even accounting for no-shows, documentation time, and the reality that not all slots fill perfectly, you can clear $200-250/hour in actual income once you factor in overhead.

But here’s the catch most psychiatrists miss: building an insurance-based telehealth practice requires either:

1. Joining existing insurance networks (which takes months, involves credentialing headaches, and limits your negotiating power), or
2. Going out-of-network (which means patients need good OON benefits or pay cash, limiting your patient pool)

And more importantly: how do you fill your schedule?

The Patient Acquisition Problem Nobody Talks About

Here’s where most psychiatrists’ telehealth fantasies crash into reality. You can be the best ADHD prescriber in your state, credentialed with every insurer, and offering convenient video appointments—but if nobody knows you exist, your schedule stays empty.

Let’s say you decide to market yourself. Your options:

SEO/Content Marketing: You could build a website, write blog posts, optimize for ‘ADHD psychiatrist [your city]’ searches. Maybe hire an SEO consultant at $2,000-5,000/month. Best case? You start seeing organic traffic in 6-12 months. During that time, you’re paying the consultant and seeing zero return.

Google Ads: Mental health keywords are expensive—$15-40+ per click in competitive markets. Let’s say you pay $25/click and get a 5% conversion rate from click to booked appointment (optimistic). That’s $500 per booked patient. And of those booked, maybe 20% no-show or cancel. So your actual cost per seen patient is $600+. You need to see that patient for multiple visits just to break even on acquisition cost.

Psychology Today and Directories: You pay $30/month for a listing, but you’re on a page with 200 other providers in your metro area. Maybe you get 2-3 inquiries per month, of which one books. That’s $30 per patient… except you also spent 2 hours setting up your profile, responding to messages, and scheduling. If your time is worth $250/hour, that’s actually $530 per patient when you account for your labor.

The real all-in cost to acquire a qualified psychiatric patient through DIY marketing typically runs $200-500+ when you factor in:

• Agency/consultant fees for marketing setup and management
• Ad spend and ongoing testing/optimization
• Your time handling inquiries, qualifying leads, and managing the sales process
• No-show and cancellation rates from cold leads who haven’t been pre-qualified
• The 6-12 month delay before SEO generates meaningful traffic
• Failed campaigns and learning curves (most first attempts at Google Ads fail)

And here’s the thing: you’re a psychiatrist, not a marketer. You went to medical school to treat patients, not to become an expert in conversion rate optimization and Facebook Pixel tracking.

The Klarity Model: Why Pay-Per-Appointment Actually Makes Sense

This is where platforms like Klarity Health change the equation entirely. Instead of spending thousands upfront on marketing with uncertain results, you pay a standard listing fee per new patient lead when someone books with you.

Let’s break down why this model actually works economically:

No upfront marketing spend: You’re not paying $3,000-5,000/month to an SEO agency while you wait for traffic. You’re not gambling $2,000 on Google Ads campaigns that might not convert. Your first dollar out goes to an actual patient who booked an appointment.

Pre-qualified patients: Klarity screens patients before they ever reach your schedule. They’ve already been matched to your specialty (ADHD medication management), verified their insurance or payment method, and confirmed they’re in a state where you’re licensed. These aren’t cold leads from a directory—they’re patients who specifically need what you offer and are ready to start treatment.

Built-in infrastructure: You’re not paying separately for:

• A telehealth platform ($50-200/month for HIPAA-compliant video)
• An e-prescribing system ($50-150/month for controlled substance e-prescribing with two-factor authentication)
• Scheduling software ($30-100/month)
• Patient intake/documentation systems ($100-300/month for a good EHR)
• HIPAA-compliant communication tools

All of this is included. When you add up what solo practitioners pay for this tech stack, it’s easily $300-500/month before you see a single patient.

You control your schedule: Unlike hospital employment or group practices, you decide how many patients you want to see and when. Want to do 20 hours a week of telehealth alongside your main practice? Done. Want to build a full-time telehealth practice? Also possible. The listing fee per patient means you only pay when you’re actually working.

Both insurance and cash-pay volume: Many telehealth platforms struggle to get on insurance panels, forcing patients to pay cash (limiting your market). Klarity works with insurance, expanding your potential patient base significantly while also serving cash-pay patients who want convenience.

Compare the models:

Traditional DIY approach:

• Month 1-6: Pay $3,000-5,000/month in marketing, see 0-5 patients → negative ROI
• Month 7-12: Maybe seeing 15-20 new patients/month if SEO starts working → spent $30,000 in marketing to get here
• Ongoing: Continuing marketing spend to maintain flow, plus tech stack costs, plus your time managing it all

Klarity approach:

• Month 1: See 10-15 patients, pay listing fee per patient → immediate positive cash flow
• Month 2-6: Volume ramps as you build availability and reputation on platform → consistent income
• Ongoing: Pay only for patients you see; no wasted marketing spend, no tech overhead

The per-patient fee is higher than what you’d pay per patient if you were a marketing genius who cracked the patient acquisition code yourself. But you’re not a marketing genius—you’re a psychiatrist. The relevant comparison isn’t ‘What could I do if I were also an expert digital marketer?’ It’s ‘What’s the guaranteed ROI option that lets me focus on clinical care?’

For most psychiatrists, especially those starting out in telehealth or building a practice in a new state, the pay-per-appointment model removes all the risk. You know exactly what your patient acquisition costs, you avoid the months of upfront investment with no return, and you can scale up or down based on your capacity.

The Cash-Pay Alternative

Some psychiatrists skip insurance entirely and go cash-only for telehealth ADHD. Typical rates: $300-500 for initial evaluation, $150-250 for follow-ups.

This works if you can fill your schedule (see above patient acquisition problem). The upside: higher per-visit revenue, no insurance hassles. The downside: you’re limiting yourself to patients who can afford $2,000-3,000/year out-of-pocket for ADHD treatment. That’s a significant portion of potential patients, especially younger adults who are most likely to seek telehealth care.

A hybrid approach—being in-network for some plans, cash-only for others, and leveraging a platform like Klarity for volume—often makes the most sense.

Compliance and Quality: How to Do This Right

The unfortunate reality: telehealth ADHD prescribing has a bad reputation in some circles, thanks to companies that essentially ran online pill mills with 10-minute ‘evaluations’ leading to stimulant prescriptions. The DEA and state medical boards remember this.

Your job is to practice medicine, not prescription retail. Here’s how:

Thorough Initial Evaluations

Take your time. A 45-60 minute initial evaluation for ADHD is appropriate and defensible. Use structured diagnostic tools (rating scales), document your reasoning, and be willing to say ‘I don’t think this is ADHD’ when the clinical picture doesn’t fit.

Common differential diagnoses you should actively consider and rule out:

• Anxiety (which can present as distractibility and restlessness)
• Depression (with concentration problems)
• Sleep disorders (sleep apnea causing daytime fatigue and attention issues)
• Substance use (especially if the patient is seeking stimulants)
• Undiagnosed learning disabilities (ADHD symptoms might actually be frustration from dyslexia, etc.)

If you’re uncertain, request prior records, psychological testing, or collateral information before prescribing.

Ongoing Monitoring

Follow up monthly initially. Check vitals periodically (every 3-6 months at minimum). If a patient repeatedly ‘loses’ prescriptions, runs out early, or shows other red flags, address it directly—and be willing to discontinue stimulants if you suspect diversion or misuse.

Document any concerning behaviors in your notes. If you ever need to defend your prescribing, your contemporaneous documentation is your best evidence that you were practicing appropriately.

PDMP Checks

Most states require checking the Prescription Drug Monitoring Program before prescribing controlled substances. Make this routine. If a patient is getting benzodiazepines from another provider, or worse, stimulants from multiple sources, you need to know.

Some red flags from PDMP:

• Multiple prescribers for controlled substances
• Getting prescriptions from out-of-state providers
• Filling prescriptions at multiple pharmacies
• Early fills (picking up medication before they should have run out)

These don’t automatically disqualify someone from treatment, but they warrant a conversation and possibly more stringent monitoring.

Professional Boundaries in Telehealth

Telehealth can blur boundaries. Patients might text you outside scheduled appointments or expect immediate responses. Establish clear communication policies upfront:

• How to reach you between visits (patient portal, not personal cell)
• Expected response times (24-48 business hours for non-urgent messages)
• When to go to ER or crisis services (if side effects or psychiatric emergency)

Your malpractice insurance should cover telehealth. If not, update your policy before you start. Most insurers now offer telehealth coverage, but confirm it explicitly covers controlled substance prescribing via telemedicine.

Why ADHD Telehealth Makes Sense Right Now

The demand for ADHD treatment—especially for adults—has exploded. Pandemic-era awareness campaigns, reduced stigma, and the rise of ‘ADHD TikTok’ (for better or worse) have led more adults to seek diagnosis and treatment. Prescription rates for ADHD medications surged in 2020-2022 (apnews.com).

Meanwhile, psychiatrist supply hasn’t kept pace. States like Texas, Florida, Pennsylvania, and much of rural America face severe shortages. Wait times to see a psychiatrist can stretch 3-6 months in many markets.

Telehealth is the solution to this mismatch. You can practice from anywhere and serve patients in multiple states (assuming you’re licensed in those states—some physicians use the Interstate Medical Licensure Compact to streamline getting licensed in multiple states).

The patients are there. The reimbursement works. The technology is mature. The main barriers are:

1. Regulatory uncertainty (which we’ve addressed—manageable through 2025, watchable for 2026)
2. Patient acquisition (which platforms like Klarity solve by handling marketing and pre-qualification)
3. Clinical workflow (which you already know—medication management is medication management)

Frequently Asked Questions

Q: Can I prescribe Adderall to a new patient I’ve never met in person?

A: Yes, under current federal waivers extended through December 2025. As of early 2026, this flexibility hasn’t been formally revoked, though the permanent status is pending federal action. You must conduct a thorough telehealth evaluation meeting the same standard of care as in-person.

Q: Do I need a separate DEA registration for telehealth prescribing?

A: No. Your existing DEA registration covers telehealth prescribing of controlled substances, as long as you’re licensed in the state where the patient is located and following federal/state rules. The DEA has discussed creating a special ‘telemedicine registration’ but hasn’t implemented it yet.

Q: What if I’m licensed in multiple states—can I see patients in all of them?

A: Yes, as long as you have both a valid medical license and DEA registration covering each state. The patient’s location (where they are during the telemedicine visit) determines which state’s laws apply. You’ll need to be credentialed with insurers in each state if you want to bill insurance.

Q: What happens if the federal waiver expires and the in-person requirement returns?

A: If that happens (and there’s political will to prevent it), you’d need an initial in-person exam before prescribing controlled substances to new patients. Existing patients could continue via telehealth. Many practices would partner with local clinics to provide ‘hub and spoke’ models—patients see someone in person once, then all follow-ups are virtual with you.

Q: Are there any ADHD medications I can prescribe without these restrictions?

A: Yes. Non-stimulant ADHD medications like atomoxetine (Strattera), guanfacine (Intuniv), and clonidine are not controlled substances and have no special telehealth restrictions. You can prescribe these to new patients via video without any federal or state barriers (beyond standard prescribing authority). Bupropion (Wellbutrin) is also sometimes used off-label for ADHD and is not controlled.

Q: How do I handle drug testing for patients on stimulants?

A: In telehealth, you can order urine drug screens through lab companies that do mobile collection or have patients go to a lab/quest diagnostics location. Many providers don’t routinely drug test ADHD patients unless there are red flags (substance use history, diversion concerns, etc.). If you do test, it’s to ensure adherence (is the stimulant in their system, showing they’re taking it) and rule out undisclosed substances, not to police patients.

Q: What should I do if I suspect a patient is diverting medication (selling it or giving it away)?

A: Document your concerns, have a direct conversation with the patient about your observations and the expectation that medication is for their use only. If diversion continues or you have strong evidence, you should discontinue the controlled substance and potentially discharge the patient from your practice. You’re not required to report suspected diversion to law enforcement unless your state mandates it, but you should stop prescribing.

Q: Do I need malpractice insurance that specifically covers telehealth?

A: Most modern malpractice policies include telehealth coverage, but you should confirm explicitly with your carrier. If your policy predates 2020, it might not cover virtual care. Update it before you start a telehealth practice.

Q: Can I prescribe stimulants via phone call, or does it have to be video?

A: Federal law under the COVID waivers allowed both video and audio-only for mental health visits. However, some states require video for controlled substance prescribing—for example, Texas law requires synchronous audio-visual (video) for prescribing controlled substances via telemedicine. Check your specific state’s requirements; when in doubt, use video.

Q: How do I verify a patient’s location if they’re traveling or could be in a different state?

A: You should ask the patient at the beginning of each visit where they’re physically located and document it. Some platforms use geolocation verification. If a patient is temporarily in another state, you can only provide care if you’re licensed in that state. Many providers have policies that patients must be in their ‘home state’ (where they’re registered on the platform) for visits.

Q: What’s the deal with Klarity Health’s model versus other telehealth platforms?

A: Klarity uses a pay-per-appointment model where you pay a listing fee per new patient lead who books with you, rather than charging monthly subscription fees or taking a percentage of your reimbursement. The platform handles patient acquisition, insurance credentialing, telehealth tech, and e-prescribing infrastructure. You control your schedule and rates. It’s designed to remove the patient acquisition risk that makes solo telehealth practices difficult to launch.

Next Steps: Getting Started with Telehealth ADHD Care

If you’re reading this far, you’re probably seriously considering adding telehealth ADHD to your practice—or building a practice around it. Here’s your action plan:

1. Verify your licensing: Do you have (or can you easily obtain) medical licenses in states where demand is high and regulations are provider-friendly? Consider the Interstate Medical Licensure Compact if you want to practice in multiple states.

2. Check your DEA registration: Is your controlled substance registration current? Make sure it covers the states where you plan to practice.

3. Understand your malpractice coverage: Confirm your policy covers telehealth and controlled substance prescribing remotely.

4. Choose your model: Are you going to:

• Build a DIY practice with your own marketing (high risk, high cost, 6+ months to revenue)
• Go cash-only and market to affluent patients (limits market, requires strong marketing)
• Join a platform like Klarity that handles patient acquisition and infrastructure (immediate patient flow, predictable costs, guaranteed ROI)

For most psychiatrists, especially those new to telehealth or building in multiple states, the platform approach removes the barriers that stop most practices before they start.

5. Set up your clinical workflow: How will you handle:

• Initial evaluations (scheduling, rating scales, documentation templates)
• Prescription monitoring (PDMP checks, when to recheck vitals)
• Pharmacy coordination (especially during medication shortages)
• Urgent issues between visits

6. Stay current on regulations: Bookmark DEA and state medical board websites. Sign up for newsletters from organizations like the American Psychiatric Association or American Telemedicine Association that track policy changes.

The opportunity is real. ADHD patients need care, telehealth removes access barriers, reimbursement works, and the regulatory path (while imperfect) is navigable. The question isn’t whether telehealth ADHD care is viable—it demonstrably is. The question is whether you want the headache of building patient acquisition infrastructure yourself, or whether you’d rather focus on clinical care and let someone else handle the marketing machinery.

If you’re tired of waiting for your phone to ring, if you’re frustrated by the 6-12 month lag time of SEO, if you want to see ADHD patients tomorrow instead of next year—explore platforms built to solve exactly this problem. Klarity Health’s provider network exists specifically to connect psychiatrists with pre-qualified patients who need ADHD treatment, removing the marketing gamble and letting you focus on what

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the